Xeris Biopharma Holdings, Inc./$XERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Ticker
$XERS
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
394
ISIN
US98422E1038
Website
XERS Metrics
BasicAdvanced
$758M
-
-$0.30
0.91
-
Price and volume
Market cap
$758M
Beta
0.91
52-week high
$6.07
52-week low
$3.59
Average daily volume
2.2M
Financial strength
Current ratio
1.72
Quick ratio
1.102
Long term debt to equity
-713.605
Total debt to equity
-765.062
Interest coverage (TTM)
-0.53%
Profitability
EBITDA (TTM)
-4.333
Gross margin (TTM)
82.21%
Net profit margin (TTM)
-20.25%
Operating margin (TTM)
-7.37%
Effective tax rate (TTM)
5.40%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-3.14%
Return on equity (TTM)
203.48%
Valuation
Price to revenue (TTM)
3.183
Price to book
-21.56
Price to tangible book (TTM)
-4.91
Price to free cash flow (TTM)
-25.828
Free cash flow yield (TTM)
-3.87%
Free cash flow per share (TTM)
-18.31%
Growth
Revenue change (TTM)
29.88%
Earnings per share change (TTM)
-35.26%
3-year revenue growth (CAGR)
51.92%
3-year earnings per share growth (CAGR)
-40.32%
Bulls say / Bears say
Xeris Biopharma reported a record first quarter in 2025, with total revenue reaching $60.1 million, a 48% increase over the same period in 2024, indicating strong product demand and effective market penetration. (xerispharma.com)
The company achieved a positive adjusted EBITDA of $4.4 million in Q1 2025, marking a significant turnaround from a loss of $4.1 million in Q1 2024, reflecting improved operational efficiency and financial health. (xerispharma.com)
Xeris entered into a worldwide license agreement for its XeriJect® formulation of teprotumumab, potentially expanding its product portfolio and opening new revenue streams. (xerispharma.com)
Despite revenue growth, Xeris reported a net loss of $9.2 million in Q1 2025, indicating ongoing challenges in achieving profitability. (xerispharma.com)
The company's total liabilities increased by 10% from 2023 to 2024, reaching $329 million, which may raise concerns about its debt levels and financial stability. (siriusinvestors.com)
Xeris's operating loss widened from $4.9 million in Q3 2023 to $12.9 million in Q3 2024, suggesting escalating operational costs that could impact future profitability. (dcf-fm)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
XERS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xeris Biopharma Holdings, Inc. stock?
Xeris Biopharma Holdings, Inc. (XERS) has a market cap of $758M as of July 03, 2025.
What is the P/E ratio for Xeris Biopharma Holdings, Inc. stock?
The price to earnings (P/E) ratio for Xeris Biopharma Holdings, Inc. (XERS) stock is 0 as of July 03, 2025.
Does Xeris Biopharma Holdings, Inc. stock pay dividends?
No, Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next Xeris Biopharma Holdings, Inc. dividend payment date?
Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders.
What is the beta indicator for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. (XERS) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.